The capital is pricing semaglutide as a metabolic platform -- four indications, one molecule, a market-cap multiple that has run 40 percent above the MSCI Healthcare index since January 2026. The trial delivering on that bet is ESSENCE, a Phase 3 study in 1,200 NASH patients, primary endpoint a two-stage histological improvement at 72 weeks, with top-line data expected Q3 2026 and a parallel NMPA Center for Drug Evaluation submission anticipated before year-end.

ESSENCE is not SUSTAIN-6 and it is not SELECT. Those were cardiovascular event trials, hard endpoints, n above 3,000. ESSENCE runs on a biopsy-defined histological composite -- a credible endpoint, accepted by FDA's hepatology division under the 2023 accelerated-approval guidance for NASH, but one that does not translate directly to cardiovascular event reduction, the asset APAC family offices have been pricing since SELECT reported in November 2023. Novo's Q1 2026 earnings disclosed CNY 3.2 billion in mainland China semaglutide revenue, driven almost entirely by the T2DM indication under NMPA approval; the liver indication is not approved in China, has no NDA submitted, and the ESSENCE data that would anchor the submission has not read out. If ESSENCE misses its primary endpoint -- as Phase 2b did in the similar NASH trial for Pfizer's lanifibranor in May 2025 -- the NMPA submission clock does not start, the platform multiple compresses, and the CKD indication (FLOW trial, reported March 2024, n equals 3,533, primary endpoint a kidney-failure composite) becomes the only hard-endpoint pillar left holding the valuation.